CD274 and neoplasm: BRAF/MEK inhibition reduces tumor burden and upregulates MHC-I/tumor antigens; inhibits ERK-MAPK-CXCL8 axis → enhances BBB permeability & T cell infiltration; PD-L1 blockade restores effector T cell function